Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Year-end report 2023

Fourth Quarter (Oct–Dec 2023) Net sales amounted to TSEK 161,868 (127,545), which is an increase of 26.9 % compared to the same period last year. The gross margin amounted to 51.9 % (58.3). Operating profit before depreciation (EBITDA) amounted to TSEK 44,520 (35,510), which corresponds to an operating margin before depreciation of 27.5 % (27.8). Operating profit (EBIT) amounted to TSEK 29,325 (24,369), which corresponds to an operating margin of 18.1 % (19.1). Earnings per share before dilution amounted to SEK 2.01 (1.76).(Comparative figures in parentheses refer to the

Himalaya Shipping Ltd. (HSHP) – Commercial Update and Key Information Relating to the Cash Distribution for January 2024

Hamilton, Bermuda, February 8, 2024 Commercial update: In January 2024, the Company achieved average time charter equivalent (“TCE”) earnings of approximately US$28,400 per day, gross[1]. The Company’s six vessels trading on a fixed time charter earned US$28,600 per day, gross, including average daily scrubber and LNG benefits on five vessels of approximately $2,800 per day. The Company’s three vessels trading on index-linked time charters earned approximately US$28,000 per day, gross, including average daily scrubber and LNG benefits of approximately US$3,000 per day. The index

The subscription price for the exercise of warrants of series TO3 in Pharmacolog has been set at SEK 0.054 per share

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Pharmacolog in Uppsala AB (“Pharmacolog” or “the Company”) completed a rights issue of units on the Nasdaq First North Growth Market in July 2023. Each unit consisted of four (4) series B shares and four (4) warrants of

Cloudberry Clean Energy ASA | CFO appointed

Oslo, Norway, 08 February 2024: Cloudberry Clean Energy ASA (Cloudberry) has today appointed Ole-Kristofer Bragnes as Chief Financial Officer (CFO). Former Chief Value Officer (CFO) Christian Helland will continue in Cloudberry as the Chief Commercial Officer (CCO) with an increased focus on value creation for the group.  Helland will as CCO lead Cloudberry’s commercial, M&A and new technologies segment.Bragnes currently serves as the Senior Financial Officer in Cloudberry, and he has over seven years of experience with capital markets transactions, debt structuring and other senior

Invitation to presentation of Storskogen’s year-end report 2023

On 15 February 2024 at 07:00 (CET), Storskogen announces its year-end report 2023. In connection with the announcement, a presentation will be held by Daniel Kaplan, CEO, and Lena Glader, CFO, followed by a Q&A session. The presentation will be held in English and starts at 09:00 (CET).The presentation and the subsequent Q&A can be followed via webcast or telephone conference. For participation via webcast, please use the following link:https://ir.financialhearings.com/storskogen-group-q4-report-2023/register If you wish to participate via telephone conference, please register via

Sleep Cycle year-end report 2023: Continued subscription growth sums up a strong full year

Gothenburg, Sweden — 8 February, 2024The fourth quarter in summary (October-December 2023) · Net sales totaled tSEK 61,254 (55,405) and increased by 10.6% (16.1%). Currency-adjusted net sales growth amounted to 5.7% (8.6%). · Operating profit amounted to tSEK 12,689 (4,549), with an operating margin of 20.7% (8.2%). Operating profit was affected by a non-cash impairment loss of tSEK 6,341. Excluding impairment, the margin was 31.1%. · Adjusted operating profit totaled tSEK 12,689 (7,351) and adjusted operating margin was 20.7% (13.3%). · The total number of paying subscribers

The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch

RaySearch Laboratories AB (publ) is proud to announce that The Royal Marsden NHS Foundation Trust, a specialist cancer center in the UK, will be the first in the world to implement online adaptive radiation therapy (OART) with RaySearch’s treatment planning system RayStation®* and oncology information system RayCare®* – including the new ARTemis* OART solution under development – in combination with the Radixact® Treatment Delivery System from Accuray.The Royal Marsden is at the forefront of radiotherapy research in the UK and globally and has been using RayStation for conventional

ExpreS2ion announces financial results for the fourth quarter and full-year 2023

Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2023. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments: “2023 unfolded in ways we had not anticipated, primarily due to a challenging funding environment and developments in our pipeline outside our control. However, we have commenced 2024 equipped with a clear, new strategic direction, a streamlined company, and a solid Phase III

Year-end report 2023 – Pricer AB

High net sales of 801 MSEK – an increase of 15 percent compared to last year.Fourth quarter 2023 • Net sales amounted to SEK 800.6 M (696.1), an increase of 15.0 percent compared to the same period last year. • Of net sales, SEK 17.5 M (11.9) refers to recurring revenue. • Gross margin amounted to 17.7 percent (15.5). • Operating profit (EBIT) amounted to SEK 20.1 M (27.9), which corresponds to an operating margin of 2.5 percent (4.0). • The company initiates a cost-saving program that is burdening the quarter with SEK 19.3 M in restructuring costs and SEK 14.8 M for

Attendo's year-end and fourth quarter report for 2023 to be published on 8 February - Invitation to presentation (NEW LINK)

On 8 February 2024 around 08:00 am (CET), Attendo will present its fourth quarter report for 2023. A webcast presentation will be held at 11:00 am (CET) on the same day.The presentation will be hosted by Attendo’s CEO Martin Tivéus and CFO Mikael Malmgren. The presentation will be held in English.   You can follow the presentation on the following page:https://ir.financialhearings.com/attendo-q4-report-2023   Analysts and investors will have the opportunity to ask questions during the presentation by calling in. To obtain call-in details, please send your request to:

XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

XNK Therapeutics AB ("XNK”) today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.XNK’s presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye’s homepage. XNK’s presentation will be followed by a short Q&A session. For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail: johan.liwing@xnktherapeutics.com About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy

BioStock: Deep dive into SynAct Pharma’s new strategy

With support from leading rheumatologists, SynAct Pharma is presenting a reshaped strategic plan for resomelagon in rheumatoid arthritis. In addition, they are planning to initiate a phase II trial with resomelagon in influenza patients and prepare the melanocortin agonist TXP-11 for clinical development. BioStock reached out to CEO Torbjørn Bjerke to learn more about the new strategic plan.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/deep-dive-into-synact-pharmas-new-strategy/ This is a press release from BioStock - Connecting

NORDEN reports annual result of USD 400 million for 2023 and continues to return cash to shareholders

ANNOUNCEMENT NO. 29 - 8 FEBRUARY 2024 NORDEN reports an annual result of USD 400 million (approx. DKK 2,760 million). For the fourth quarter of 2023 net profit amounted to USD 43 million (approx. DKK 297 million).Freight Services & Trading posted a net profit of USD 133 million (approx. DKK 918 million) and Assets & Logistics a net profit of USD 268 million (approx. DKK 1,850 million) for the full-year 2023.     Free cashflow for the full-year 2023 amounted to USD 264 million (approx. DKK 1,822 million) and with a positive free cashflow of USD 30 million (DKK 207 million) for the

Rototilt’s joysticks win award again – winner of the “Good Design Award”

With two design awards in 2022 and a German Design Award in 2023, RC Joysticks from Rototilt have secured another win, this time receiving a Good Design Award in the “Electronics” category. “It was a meticulous design process, and we’re glad to see the appreciation, both in terms of the response from users and the industry,” says Caroline Jonsson, Product Manager at Rototilt.Rototilt, a Swedish tiltrotator manufacturer with subsidiaries worldwide, including North America, released the new joysticks for excavators and tiltrotators, RC Joysticks, in late 2022. Since then, they have won three

Gasum starts an expansion project at Riihimäki biogas plant

To enhance production efficiency, Gasum’s Riihimäki biogas plant in Finland is undergoing a significant conversion focused on the treatment of the digestate. The project demonstrates Gasum’s commitment to increasing the production of biogas to bring more renewable energy to the market and at the same time promoting the use of recycled nutrients.Nordic energy company Gasum has decided to invest EUR 7.5 million in a project aimed at expanding and enhancing the current biogas plant in Riihimäki, Finland. Operational since 2016, the plant contributes around 45 gigawatt hours (GWh) of biomethane

Invitation to the Annual General Meeting

Neste Corporation, Stock Exchange Release, 8 February 2024, 09:05 a.m. (EET) Neste Corporation's (the "Company") shareholders are hereby invited to the Annual General Meeting of Shareholders (the "AGM") to be held on Wednesday, 27 March 2024, beginning at 10 am EET, in the Conference Centre of Helsinki Expo and Convention Centre, entrance at Rautatieläisenkatu 3, 00520 Helsinki. Registration and the distribution of voting papers will begin at the AGM venue at 9 am EET. Shareholders can also exercise their right to vote by voting in advance. Instructions for advance voting are

Invitation to presentation in conjunction with Acroud's year-end report for 2023

On Thursday 22th February at 08:00 a.m. CET Acroud's year-end report for 2023 will be published. At 10:00 a.m. CET the same day, a presentation of Acroud's year-end report for 2023 will be presented.CEO Robert Andersson and CFO Andrzej Mieszkowicz will present the report, followed by a Q&A session. The presentation will be held in English and will be webcasted live via https://financialhearings.com/event/48817 The webcast and the presentation slides will be published on www.acroud.com For further information, please contact: Robert Andersson, President and CEO +356 9999 8017

Africa Oil Provides Namibia and Nigeria Operational Update

VANCOUVER, BC,  February 8, 2024 /CNW/ -  (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, “AOC” or the “Company”) notes the statements made by TotalEnergies, the operator of Block 2913B offshore Namibia, in their 2023 Results Presentation, delivered yesterday, regarding the ongoing exploration and appraisal activities on Block 2913B.              Africa Oil has an interest in this block through its 31.1% shareholding in Impact Oil & Gas Limited (“Impact”).   Mangetti-1X exploration well has intersected hydrocarbon-bearing intervals in the Mangetti fan prospect, a

Year-end report 2023

Strong growth in recurring servicesOctober - December 2023  · Revenues decreased by 5.6 per cent to SEK 1,360.0 million (1,440.1). · Adjusted EBITA decreased by 10.9 per cent and amounted to SEK 91.1 million (102.2), corresponding to an adjusted EBITA margin of 6.7 per cent (7.1). · Earnings before tax amounted to SEK 82.6 million (86.0). · Earnings after tax amounted to SEK 65.5 million (64.0). · Earnings per share amounted to SEK 2.39 (2.34). · New contracts relating to cloud services worth SEK 197.0 million (142.0) were contracted, an increase by 38.7 per cent. ·

Year-End Report January – December 2023

A STRONG END TO A STRONG YEARFinancial development fourth quarter 2023 · Net sales increased by 12% to SEK 353 million (315). · The gross margin was 48.2% (45.8). · Adjusted EBITDA amounted to SEK 59.8 million (43.4), equivalent to an adjusted operating margin of 17.0% (13.8). · Operating profit (EBIT) amounted to SEK 41.4 million (31.5), corresponding to an operating margin of 11.7% (10.0). · Order intake increased by 51% to SEK 408 million (271). · Operating cash flow amounted to SEK 26.2 million (-49.3). Financial development January - December 2023 · Net

Sivers Semiconductors Reports Record Fourth-Quarter and Fiscal-Year 2023 Results

A record-breaking year and quarter, leads to profitability in Q4, 2023·Fourth-quarter revenue was SEK 73.882 million, up 48% year-over-year (YoY). ·Full-year revenue was SEK 236.334 million, up 78% year-over-year (YoY).  ·Adjusted EBITDA totaled SEK 21.032 million (–16.943). ·Company is finalizing a SEK 50 million loan facility extension with existing lenders; thus eliminating the need for capital contributions from shareholders. Kista, Sweden // Feb. 8, 2024 // Sivers  Semiconductors AB (STO: SIVE) Fourth quarter October-December 2023 · Net sales amounted

Polygiene Group invites you to a presentation of the fourth quarter 2023

Polygiene Group will publish its quarterly report for the fourth quarter (October-December) on February 15, 2024, at 8.00 CET. In connection to the announcement, Polygiene Group invites you to a video conference on the same day at 10.00 CET.· Presentation of the quarterly report, CEO Ulrika Björk · Review of the financial results, CFO Niklas Blomstedt The conference is expected to last 45 minutes and will be held in English.         Registration is made via the link below no later than February 14, 2024. Instructions regarding access to the conference will be sent out via e-mail

Corem signs ten-year lease for 5,160 sq.m. with SOS International in Copenhagen

Corem has signed a ten-year lease agreement with SOS International regarding 5,160 sq.m. of office space in Fairway House, Copenhagen. Move-in is planned for early September 2024. The office, which is on three floors, will be adapted to best respond to SOS International's needs and requirements, with detailed interior designing in collaboration with the tenant. "We have been looking for the right premises for our new headquarters for a long time and we have found it in Fairway House, where, in addition to a central location, we get a good working environment with high

There are no items matching the current filter
There are no more items matching the current filter
Back to top